Although the traditional therapeutic strategies have been tremendously improved, such as tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) and immune checkpoint inhibitors [6–8], have been successfully used in clinical practice [9], but the five-year overall survival of lung cancer of all stages combined remains as low as 15% [10]. The gene discussed is EGFR; the disease is lung cancer.